Fusion of ubiquitin to HIV gag impairs human monocyte-derived dendritic cell maturation and reduces ability to induce gag T cell responses

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Herath, Shanthi ^a   Benlahrech, Adel ^a   Papagatsias, Timos ^a   Athanasopoulos, Takis ^b   Bouzeboudjen, Zineb ^a   Hervouet, Catherine ^c   Klavinskis, Linda ^c   Meiser, Andrea ^a   Kelleher, Peter ^a   Dickson, George ^b   Patterson, Steven ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; HYBRID PROTEIN; INTERLEUKIN 10; PROTEASOME; UBIQUITIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CASE REPORT; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL MATURATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; GENE EXPRESSION REGULATION; GENE INSERTION; GROUP SPECIFIC ANTIGEN GENE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MART GENE; MONOCYTE; MOUSE; NONHUMAN; PROTEIN STABILITY; PROTEIN TARGETING; T LYMPHOCYTE; TRANSGENE; UBIQUITINATION; VIRUS GENE;

AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DENDRITIC CELLS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, INBRED C57BL; MONOCYTES; TRANSDUCTION, GENETIC; TRANSGENES; UBIQUITIN; UBIQUITINATION;

EID: 84895550252     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088327     Document Type: Article

References (47)

1. Verkoczy L, Kelsoe G, Moody MA, Haynes BF (2011) Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr Opin Immunol 23: 383-390.
2. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, et al. (2013) Antibodies in HIV-1 vaccine development and therapy. Science 341: 1199-1204.
3. Gamble LJ, Matthews QL (2011) Current progress in the development of a prophylactic vaccine for HIV-1. Drug Design, Development and Therapy 5: 9-26.
4. Elahi S, Dinges WL, Lejarcegui N, Laing KJ, Collier AC, et al. (2011) Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nat Med 17: 989-995.
5. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al. (2007) CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13: 46-53. (Pubitemid 46067385)
6. Day CL, Kiepiela P, Leslie AJ, van der Stok M, Nair K, et al. (2007) Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection. J Virol 81: 434-438. (Pubitemid 44975185)
7. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, et al. (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473: 523-527.
8. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, et al. (2009) Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15: 293-299.
9. Goldwich A, Hahn SS, Schreiber S, Meier S, Kampgen E, et al. (2008) Targeting HIV-1 Gag into the defective ribosomal product pathway enhances MHC class I antigen presentation and CD8+ T cell activation. J Immunol 180: 372-382.
10. Yewdell JW (2006) Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25: 533-543.
11. Turnbull EL, Wong M, Wang S, Wei X, Jones NA, et al. (2009) Kinetics of expansion of epitope-specific T cell responses during primary HIV-1 infection. J Immunol 182: 7131-7145.
12. Goulder PJ, Altfeld MA, Rosenberg ES, Nguyen T, Tang Y, et al. (2001) Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 193: 181-194.
13. Wilson JD, Ogg GS, Allen RL, Goulder PJ, Kelleher A, et al. (1998) Oligoclonal expansions of CD8(+) T cells in chronic HIV infection are antigen specific. J Exp Med 188: 785-790. (Pubitemid 28387942)
14. Janeway C (2005) Immunobiology : the immune system in health and disease. New York: Garland Science. xxiii, 823 p.
15. Lecker SH, Goldberg AL, Mitch WE (2006) Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 17: 1807-1819. (Pubitemid 44036165)
16. Kloetzel PM (2004) The proteasome and MHC class I antigen processing. Biochim Biophys Acta 1695: 225-233.
17. Huang L, Marvin JM, Tatsis N, Eisenlohr LC (2011) Cutting Edge: Selective role of ubiquitin in MHC class I antigen presentation. J Immunol 186: 1904-1908.
18. Rouard H, Klonjkowski B, Marquet J, Lahet C, Mercier S, et al. (2003) Adenoviral transgene ubiquitination enhances mouse immunization and class I presentation by human dendritic cells. Hum Gene Ther 14: 1319-1332. (Pubitemid 37174756)
19. Rodriguez F, Zhang J, Whitton JL (1997) DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol 71: 8497-8503. (Pubitemid 27446431)
20. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245-252. (Pubitemid 28155090)
21. Shortman K, Liu YJ (2002) Mouse and human dendritic cell subtypes. Nat Rev Immunol 2: 151-161. (Pubitemid 37336516)
22. Shortman K, Naik SH (2007) Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 7: 19-30. (Pubitemid 46020824)
23. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, et al. (2010) Development of monocytes, macrophages, and dendritic cells. Science 327: 656-661.
24. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, et al. (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332. (Pubitemid 28144092)
25. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5: 296-306. (Pubitemid 40516155)
26. Lu W, Wu X, Lu Y, Guo W, Andrieu JM (2003) Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 9: 27-32. (Pubitemid 36098256)
27. Lu W, Arraes LC, Ferreira WT, Andrieu JM (2004) Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 10: 1359-1365. (Pubitemid 40022718)
28. Harari A, Bart PA, StohrW, Tapia G, Garcia M, et al. (2008) An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205: 63-77. (Pubitemid 351185716)
29. Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, et al. (2008) Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 31: 294-309. (Pubitemid 351441001)
30. Luo J, Deng ZL, Luo X, Tang N, Song WX, et al. (2007) A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2: 1236-1247. (Pubitemid 46908240)
31. Bachy V, Hervouet C, Becker PD, Chorro L, Carlin LM, et al. (2013) Langerin negative dendritic cells promote potent CD8+ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays. Proc Natl Acad Sci U S A 110: 3041-3046.
32. Benlahrech A, Harris J, Meiser A, Papagatsias T, Hornig J, et al. (2009) Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci U S A 106: 19940-19945.
33. Van Gulck ER, Vanham G, Heyndrickx L, Coppens S, Vereecken K, et al. (2008) Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals. J Virol 82: 3561-3573. (Pubitemid 351429932)
34. Dalod M, Dupuis M, Deschemin JC, Sicard D, Salmon D, et al. (1999) Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J Virol 73: 7108-7116. (Pubitemid 29383190)
35. Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, et al. (2006) Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 80: 4717-4728.
36. Ecker DJ, Stadel JM, Butt TR, Marsh JA, Monia BP, et al. (1989) Increasing gene expression in yeast by fusion to ubiquitin. J Biol Chem 264: 7715-7719. (Pubitemid 19119194)
37. Rodriguez F, An LL, Harkins S, Zhang J, Yokoyama M, et al. (1998) DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J Virol 72: 5174-5181. (Pubitemid 28215699)
38. Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Lienard D, et al. (1999) High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 190: 705-715. (Pubitemid 29428652)
39. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, et al. (2000) HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 192: 63-75. (Pubitemid 30470807)
40. Tobery TW, Siliciano RF (1997) Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J Exp Med 185: 909-920. (Pubitemid 27119875)
41. Dobano C, Rogers WO, Gowda K, Doolan DL (2007) Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines. Immunol Lett 111: 92-102. (Pubitemid 47212489)
42. Fu TM, Mylin LM, Schell TD, Bacik I, Russ G, et al. (1998) An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. J Virol 72: 1469-1481. (Pubitemid 28116935)
43. Vidalin O, Tanaka E, Spengler U, Trepo C, Inchauspe G (1999) Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination. DNA Cell Biol 18: 611-621. (Pubitemid 29387798)
44. Hahn S, Setz C, Wild J, Schubert U (2011) The PTAP sequence within the p6 domain of human immunodeficiency virus type 1 Gag regulates its ubiquitination and MHC class I antigen presentation. J Immunol 186: 5706-5718.
45. Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23: 515-548. (Pubitemid 40563179)
46. Baravalle G, Park H, McSweeney M, Ohmura-Hoshino M, Matsuki Y, et al. (2011) Ubiquitination of CD86 is a key mechanism in regulating antigen presentation by dendritic cells. J Immunol 187: 2966-2973.
47. Corcoran K, Jabbour M, Bhagwandin C, Deymier MJ, Theisen DL, et al. (2011) Ubiquitin-mediated regulation of CD86 protein expression by the ubiquitin ligase membrane-associated RING-CH-1 (MARCH1). J Biol Chem 286: 37168-37180.